Dosing of antimicrobials in obesity: Difference between revisions
From IDWiki
m (→) |
(→) |
||
(5 intermediate revisions by the same user not shown) | |||
Line 29: | Line 29: | ||
| female: <math>\frac{9270 \times TBW}{8780} + 244 \times BMI</math> |
| female: <math>\frac{9270 \times TBW}{8780} + 244 \times BMI</math> |
||
|} |
|} |
||
== Calculating CrCl == |
|||
[https://globalrph.com/medcalcs/salazar-corcoran-calc/ Salazer-Cocoran equation] is more reliable in obesity but requires both height and weight. |
|||
== Antibiotics == |
== Antibiotics == |
||
Line 34: | Line 37: | ||
==== Penicillins ==== |
==== Penicillins ==== |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! Notes |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|- |
|- |
||
Line 59: | Line 62: | ||
==== Cephalosporins ==== |
==== Cephalosporins ==== |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! Notes |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|- |
|- |
||
Line 69: | Line 72: | ||
| [[Cefazolin]] |
| [[Cefazolin]] |
||
| 1-2 g IV q8h |
| 1-2 g IV q8h |
||
| 2 |
| 2 g IV q6h once ≥120 kg |
||
| |
| |
||
|- |
|- |
||
Line 99: | Line 102: | ||
==== Carbapenems ==== |
==== Carbapenems ==== |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! Notes |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|- |
|- |
||
Line 124: | Line 127: | ||
=== Quinolones === |
=== Quinolones === |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! Notes |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|- |
|- |
||
Line 144: | Line 147: | ||
=== Macrolides === |
=== Macrolides === |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! Notes |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|} |
|} |
||
=== Tetracyclines === |
=== Tetracyclines === |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! Notes |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|} |
|} |
||
=== Aminoglycosides === |
=== Aminoglycosides === |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! Notes |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|- |
|- |
||
Line 174: | Line 177: | ||
=== Others === |
=== Others === |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! Notes |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|- |
|- |
Latest revision as of 16:36, 8 June 2023
Calculating Body Weight
Weight-based dosing can use total body weight (TBW) in some instances, but often requires adjustments.
Statistic | Equation | Notes |
---|---|---|
Body mass index (BMI) (kg/m2) | kg and m | |
Body surface area (BSA) (m2) | kg and cm | |
Ideal body weight (IBW) (kg) | male: Failed to parse (unknown function "\small"): {\displaystyle 50 + 2.3 \times \small{\text{(inches over 5 ft)}}} | in inches |
female: Failed to parse (unknown function "\small"): {\displaystyle 45.5 + 2.3 \times \small{\text{(inches over 5 ft)}}} | ||
Adjusted body weight (ABW) (kg) | C = 0.3 to 0.4 | |
Lean body weight (LBW) (kg) | male: | |
female: |
Calculating CrCl
Salazer-Cocoran equation is more reliable in obesity but requires both height and weight.
Antibiotics
β-lactams
Penicillins
Drug | Usual Dose | Obesity | Notes |
---|---|---|---|
Amoxicillin | 250-500 mg q8h | 1 g PO q8h | |
Ampicillin | 1-2 g q4-6h | 2 g IV q4h | |
Nafcillin | 2 g IV q4h | ||
Piperacillin-tazobactam | 4.5 g IV q8h (q6h for Pseudomonas) | Prolonged infusion |
Cephalosporins
Drug | Usual Dose | Obesity | Notes |
---|---|---|---|
Cephalexin | 500-1000 g PO qid | 1000 g PO qid | |
Cefazolin | 1-2 g IV q8h | 2 g IV q6h once ≥120 kg | |
Cefipime | 2 g IV q8h | 2 g IV q8h prolonged infusion | |
Ceftazidime | 1-2 g IV q8h | 2 g IV q8h prolonged infusion | |
Ceftazidime-avibactam | Usual dose | ||
Ceftolozane-tazobactam | Usual dose | ||
Ceftaroline | Consider q8h |
Carbapenems
Drug | Usual Dose | Obesity | Notes |
---|---|---|---|
Doripenem | Consider extended infusion | ||
Ertapenem | 1 g IV q24h | Usual dose | |
Imipenem | Usual dose | ||
Meropenem | 500 mg q6h (1 g IV q8h for febrile neutropenia) | Consider prolonged infusion |
Quinolones
Drug | Usual Dose | Obesity | Notes |
---|---|---|---|
Ciprofloxacin | 500-750 mg PO q12h or 400 mg IV q6-8h | 400 mg IV q8h or 750 mg PO q12h | |
Levofloxacin | 500-750 mg PO q24h | Consider up to 1000 mg PO q24h | |
Moxifloxacin | 400 mg q24h | Usual dose |
Macrolides
Drug | Usual Dose | Obesity | Notes |
---|
Tetracyclines
Drug | Usual Dose | Obesity | Notes |
---|
Aminoglycosides
Drug | Usual Dose | Obesity | Notes |
---|---|---|---|
Amikacin | 15 mg/kg | Use ABW0.4 | Use Hartford nomogram with a (halved) random level |
Gentamicin | 7 mg/kg | Use ABW0.4 | Use Hartford nomogram with a random level |
Tobramycin | 7 mg/kg | Use ABW0.4 | Use Hartford nomogram with a random level |
Others
Drug | Usual Dose | Obesity | Notes |
---|---|---|---|
Aztreonam | 2 g IV q6-8h | ||
Colistin | 5 mg CBA/kg IBW x1 loading (max 300 mg) followed by 5 mg/kg/day divided q8h | Use IBW | Max 360 mg daily (nephrotoxicity) |
Polymyxin B | Use ABW0/4 | Max 200 mg or 2 MU daily (toxicity) | |
Clindamycin | 300-450 mg PO q6-8h 600-900 mg IV q8h |
600 mg IV q6h 900 mg IV q8h 450-600 mg PO q6h 600-900 mg PO q8h |
Max 2700 mg daily, or 4800 mg daily IV if life-threatening |
Dalbavancin | Usual dose | ||
Daptomycin | 4-6 mg/kg q24h | Use ABW0.4 | |
Linezolid | 600 mg PO/IV q12h | Usual dose | |
Oritavancin | Usual dose | ||
TMP-SMX | Up to 320 mg(TMP) PO q12h 8-10 mg(TMP)/kgABW in divided doses |
Consider ABW0.4 when doing high dose | |
Telavancin | Usual dose | ||
Tigecycline | Usual dose | ||
Vancomycin | 20-25 mg/kg load (max 2.5 g) 10-15 mg/kg q12h (maintenance) |
Use TBW; or 25-30 mg/kg load and 15 mg/kg q12h with ABW0.4 |
Further Reading
- Comprehensive Guidance for Antibiotic Dosing in Obese Adults. Pharmacotherapy. 2017;37(11):1415-1431. doi: 10.1002/phar.2023